INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals for alleged violations of securities laws due to misleading statements regarding its manufacturing capabilities and regulatory submissions [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Inovio's securities between October 10, 2023, and December 26, 2025, are encouraged to participate in the lawsuit before the deadline of April 7, 2026 [2]. - The lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device and the likelihood of filing the INO-3107 Biologics License Application (BLA) by the second half of 2024 [4]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio suffered from manufacturing deficiencies and failed to provide sufficient evidence for an FDA priority review or accelerated approval for its BLA [4]. - As a result of these misleading statements, investors experienced damages when the truth about Inovio's situation was revealed [4].